Search

Your search keyword '"Mitsudomi, T."' showing total 631 results
Start Over Author "Mitsudomi, T." Language english
631 results on '"Mitsudomi, T."'

1. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer

Author

Hotta, K., Hida, T., Nokihara, H., Morise, M., Kim, Y.H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Kumagai, T., Watanabe, S., Goto, K., Satouchi, M., Kozuki, T., Shukuya, T., Nakagawa, K., Mitsudomi, T., Yamamoto, N., Asakawa, T., Yoshimoto, T., Takata, S., and Tamura, T.

Published
2022
Full Text
View/download PDF

2. Consensus for HER2 alterations testing in non-small-cell lung cancer

Author

Ren, S., Wang, J., Ying, J., Mitsudomi, T., Lee, D.H., Wang, Z., Chu, Q., Mack, P.C., Cheng, Y., Duan, J., Fan, Y., Han, B., Hui, Z., Liu, A., Liu, J., Lu, Y., Ma, Z., Shi, M., Shu, Y., Song, Q., Song, X., Song, Y., Wang, C., Wang, X., Xu, Y., Yao, Y., Zhang, L., Zhao, M., Zhu, B., Zhang, J., Zhou, C., and Hirsch, F.R.

Published
2022
Full Text
View/download PDF

3. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges

Author

Fujino T, Suda K, and Mitsudomi T

Subjects
non-small cell lung cancer, met exon 14 skipping, capmatinib, tepotinib, resistance mechanisms, immune checkpoint inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, JapanCorrespondence: Tetsuya MitsudomiKindai University Faculty of Medicine, Division of Thoracic Surgery, Department of Surgery, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511, JapanTel +81 72 366 0221Fax +81 72 365 7161Email mitsudom@med.kindai.ac.jpAbstract: MET exon 14 skipping mutation (MET∆ex14) is present about 3% of non-small cell lung cancers (NSCLCs). NSCLC patients with MET∆ex14 are characterized by an average age of over 70 years at diagnosis, a smoking history and a higher frequency in pleomorphic carcinoma and adenosquamous cell carcinoma than in adenocarcinoma. It has also been reported that NSCLCs with MET∆ex14 often have codriver alterations such as EGFR amplification (6– 28%), FGFR1 alterations (5– 17%), KRAS alterations (∼ 8%), BRAF alterations (∼ 21%), or PIK3CA mutation/amplification (∼ 14%). In 2020, the approval of two MET-tyrosine kinase inhibitors (TKIs), capmatinib and tepotinib, for NSCLCs carrying MET∆ex14 dawned a new era for MET-targeted therapy. These drugs yielded progression-free survival of 5.4− 12.4 months in clinical trials; however, it has also been reported that one-third to half of patients show inherent resistance to MET-TKIs. In addition, the emergence of acquired resistance to MET-TKIs is inevitable. In this review, we summarize the clinical and molecular characteristics of NSCLCs with MET∆ex14, the efficacy and safety of capmatinib and tepotinib, the inherent and acquired resistance mechanisms to MET-TKIs, and new treatment strategies for NSCLCs with MET∆ex14 in the near future.Keywords: non-small cell lung cancer, MET exon 14 skipping, capmatinib, tepotinib, resistance mechanisms, immune checkpoint inhibitors

Published
2021

4. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

Author

Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K., and Mitsudomi, T.

Published
2019
Full Text
View/download PDF

8. 124P Phase II study of neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable stage IIIA-B N2 non-small cell lung cancer: SQUAT trial (WJOG 12119L)

Author

Miyoshi, T., Hamada, A., Soh, J., Hata, A., Nakamatsu, K., Shimokawa, M., Yatabe, Y., Suzuki, J., Tsuboi, M., Horinouchi, H., Yoshino, I., Masayuki, T., Toyooka, S., Okada, M., Go, T., Yamashita, M., Nishimura, Y., Yamamoto, N., Nakagawa, K., and Mitsudomi, T.

Published
2022
Full Text
View/download PDF

10. Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond

Author

Suda K and Mitsudomi T

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Kenichi Suda,1,2 Tetsuya Mitsudomi1 1Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan; 2Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Abstract: Lung cancers with epidermal growth factor receptor (EGFR) gene mutation account for ~40% of adenocarcinoma in East Asians and ~15% of that in Caucasians, which makes them one of the most common molecularly defined lung cancer subsets. The role of EGFR mutation as a strong predictive biomarker of response to EGFR-tyrosine kinase inhibitors (TKIs) was finally confirmed by the biomarker analysis of Iressa Pan-Asian Study (IPASS). Since the 2004 discovery of EGFR mutation in lung cancer, the EGFR mutation and EGFR-TKI treatment have been widely studied. These include characteristics of lung cancers with EGFR mutations; clinical efficacies and adverse effects of EGFR-TKIs in patients with EGFR-mutated lung cancers; development of novel EGFR-TKIs that may prolong progression-free survival of these patients or overcome resistance to first-generation EGFR-TKIs (gefitinib and erlotinib); optimal treatment schedules for EGFR-TKIs to delay emergence of resistance; molecular mechanisms of acquired resistance to EGFR-TKIs; treatment strategies after patients acquire resistance to EGFR-TKIs; and predictive biomarkers for EGFR-TKIs among patients with EGFR-mutated lung cancers. Some of these results are widely accepted, while others are apparent only in cell line models, preclinical animal models, or retrospective analyses (and sometimes conflict with each other). In this review, we summarize accumulated reports from the past decade, especially focusing on unanswered but important clinical questions in treating patients with EGFR-mutated lung cancers. Keywords: epidermal growth factor receptor mutation, predictive biomarkers, personalized therapy, molecular target, adjuvant therapy, acquired resistance

Published
2013

11. Corrigendum to ‘Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer’: [ESMO Open Volume 7 Issue 1 (2022) 100395]

Author

Ren, S., Wang, J., Ying, J., Mitsudomi, T., Lee, D.H., Wang, Z., Chu, Q., Mack, P.C., Cheng, Y., Duan, J., Fan, Y., Han, B., Hui, Z., Liu, A., Liu, J., Lu, Y., Ma, Z., Shi, M., Shu, Y., Song, Q., Song, X., Song, Y., Wang, C., Wang, X., Xu, Y., Yao, Y., Zhang, L., Zhao, M., Zhu, B., Zhang, J., Zhou, C., and Hirsch, F.R.

Published
2022
Full Text
View/download PDF

18. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)

Author

Yoshioka, H., Azuma, K., Yamamoto, N., Takahashi, T., Nishio, M., Katakami, N., Ahn, M. J., Hirashima, T., Maemondo, M., Kim, S. W., Kurosaki, M., Akinaga, S., Park, K., Tsai, C. M., Tamura, T., Mitsudomi, T., and Nakagawa, K.

Published
2015
Full Text
View/download PDF

20. Molecular Pathogenesis of Lung Cancer : Mutations in Dominant and Recessive Oncogenes, and the Expression of Opioid and Nicotine Receptors in the Pathogenesis of Lung Cancer

Author

Carbone, D., Maneckjee, R., D’Amico, D., Bader, S., Bodner, S., Chiba, I., Fedorko, J., Linnoila, I., Mitsudomi, T., Nau, M., Pass, H., Oie, H., Russell, E., Takahashi, T., Unger, T., Whang-Peng, J., Gazdar, A., Minna, J., Rhim, Johng S., editor, and Dritschilo, Anatoly, editor

Published
1991
Full Text
View/download PDF

29. Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women

Author

Wong, J.Y.Y., Hsiung, C.A., Matsuo, K., Wong, M.P., Seow, W.J., Song, M., Chang, I.-S., Chatterjee, N., Hu, W., Wu, C., Mitsudomi, T., Zheng, W., Kim, J.H., Seow, A., Caporaso, N.E., Shin, M.-H., Chung, L.P., An, S.-J., Zheng, H., Yatabe, Y., Kim, Y.T., Cai, Q., Kim, Y.-C., Bassig, B.A., Ho, J.C.M., Ji, B.-T., Daigo, Y., Ito, H., Momozawa, Y., Ashikawa, K., Kamatani, Y., Honda, T., Hosgood, H.D., Sakamoto, H., Kunitoh, H., Tsuta, K., Watanabe, S.-I., Kubo, M., Miyagi, Y., Nakayama, H., Matsumoto, S., Tsuboi, M., Goto, K., Song, L., Hua, X., Takahashi, A., Goto, A., Minamiya, Y., Shimizu, K., Tanaka, K., Wei, F., Matsuda, F., Kim, Y.H., Oh, I.-J., Song, F., Su, W.-C., Chang, G.-C., Chen, K.-Y., Chien, L.-H., Xiang, Y.-B., Kweon, S.-S., Lee, K.-M., Blechter, B., Qian, B., Lu, D., Jeon, H.-S., Hsiao, C.-F., Sung, J.S., Tsai, Y.-H., Jung, Y.J., Chung, C.C., Burdett, L., Yeager, M., Hutchinson, A., Berndt, S.I., Pang, H., Choi, J.E., Park, K.H., Sung, S.W., Zhu, M., Guan, P., Tan, W., Hsin, M., Sit, K.-Y., Ho, J., Choi, Y.Y., Kim, J.S., Yoon, H.I., Park, I.K., Xu, P., He, Q., Perng, R.-P., Vermeulen, R., Lim, W.-Y., Chen, K.-C., Jin, L., Jiang, S.-S., Yamaji, T., Hicks, B., Wyatt, K., Dai, J., Jin, G., Song, B., Cheng, S., Cui, P., Iwasaki, M., Shimazu, T., Tsugane, S., Fei, K., Wu, G., Lin, H.-C., Fang, Y.-H., Tsai, F.-Y., Hsieh, W.-S., Yu, J., Stevens, V.L., Laird-Offringa, I.A., Marconett, C.N., Rieswijk, L., Chao, A., Shu, X.-O., Lin, D., Chen, K., Zhou, B., Kohno, T., Shen, H., Chanock, S.J., Rothman, N., Lan, Q., IRAS OH Epidemiology Chemical Agents, and dIRAS RA-2

Subjects
Lung adenocarcinoma, Pathway analysis, Mendelian randomization, Tuberculosis, Lung cancer
Abstract

We investigated whether genetic susceptibility to tuberculosis (TB) influences lung adenocarcinoma development among never-smokers using TB genome-wide association study (GWAS) results within the Female Lung Cancer Consortium in Asia. Pathway analysis with the adaptive rank truncated product method was used to assess the association between a TB-related gene-set and lung adenocarcinoma using GWAS data from 5512 lung adenocarcinoma cases and 6277 controls. The gene-set consisted of 31 genes containing known/suggestive associations with genetic variants from previous TB-GWAS. Subsequently, we followed-up with Mendelian Randomization to evaluate the association between TB and lung adenocarcinoma using three genome-wide significant variants from previous TB-GWAS in East Asians. The TB-related gene-set was associated with lung adenocarcinoma (p = 0.016). Additionally, the Mendelian Randomization showed an association between TB and lung adenocarcinoma (OR = 1.31, 95% CI: 1.03, 1.66, p = 0.027). Our findings support TB as a causal risk factor for lung cancer development among never-smoking Asian women.

Published
2020

34. 932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816

Author

Felip, E., Wang, C., Ciuleanu, T-E., Saylors, G., Tanaka, F., Chen, K-N., Ito, H., Girard, N., Lu, S., Provencio Pulla, M., Mitsudomi, T., Awad, M., Forde, P.M., Lawrance, R., Taylor, F., Worthy, G., Blum, S.I., Vo, L., Cai, J.L., and Spicer, J.

Published
2022
Full Text
View/download PDF

45. The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016

Author

Tan, DSW, Yom, SS, Tsao, MS, Pass, HI, Kelly, K, Peled, N, Yung, RC, Wistuba, II, Yatabe, Y, Unger, M, Mack, PC, Wynes, MW, Mitsudomi, T, Weder, W, Yankelevitz, D, Herbst, RS, Gandara, DR, Carbone, DP, Bunn, PA, Mok, TSK, Hirsch, FR, University of Zurich, and Mok, Tony S K

Subjects
Non-small cell lung cancer, 10255 Clinic for Thoracic Surgery, 2740 Pulmonary and Respiratory Medicine, Resistance, Tyrosine kinase inhibitor, Brain metastases, 610 Medicine & health, 2730 Oncology, Therapy, EGFR mutation, respiratory tract diseases
Abstract

© 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent "actionable" alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer commissioned consensus statement, key pathologic, diagnostic, and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of repeat biopsies and use of circulating free DNA for molecular studies. With the rapid pace of progress in treating EGFR-mutant NSCLC, this statement provides a state-of-theart review of the contemporary issues in managing this unique subgroup of patients.

Published
2016

46. 1440PD - JIPANG study: Randomized phase III study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status

Author

Tsuboi, M., Kenmotsu, H., Yamanaka, T., Yoshiya, K., Takahashi, T., Ueno, T., Goto, K., Daga, H., Ikeda, N., Sugio, K., Seto, T., Toyooka, S., Date, H., Mitsudomi, T., Okamoto, I., Yokoi, K., Saka, H., Okamoto, H., Takiguchi, Y., and Yamamoto, N.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results